Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/920465/000092046518000007/ljpc-201710xk.htm
SEC Filings
LJPC Annual Reports
LJPC Quarterly Reports
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
10-Q Quarterly Report May 2019
10-Q Quarterly Report May 2022
10-Q Quarterly Report November 2021
10-Q Quarterly Report August 2021
10-Q Quarterly Report May 2021
10-Q Quarterly Report November 2020
10-Q Quarterly Report August 2020
10-Q Quarterly Report May 2020
10-Q Quarterly Report November 2019
10-Q Quarterly Report August 2019
10-Q Quarterly Report May 2019
LJPC Corporate News
Financial Exhibit
Other Events February 2022
Financial Exhibit
Other Events November 2021
Vote of Security Holders July 2021
Financial Exhibit
New Agreement January 2021
Ending Agreement
Financial Exhibit December 2020
Accountant Change
Financial Exhibit November 2020
Event for Officers October 2020
Event for Officers October 2020
Event for Officers September 2020
Ending Agreement August 2020
Financial Exhibit
Other Events
Other Events
February 2022
Financial Exhibit
Other Events
Other Events
November 2021
Vote of Security Holders
July 2021
Financial Exhibit
New Agreement
New Agreement
January 2021
Ending Agreement
Financial Exhibit
Financial Exhibit
December 2020
Accountant Change
Financial Exhibit
Financial Exhibit
November 2020
Event for Officers
October 2020
Event for Officers
October 2020
Event for Officers
September 2020
Ending Agreement
August 2020
Last10K.com | 10-K Annual Report Thu Feb 22 2018
Document and Entity Information - USD ($) | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2017 | Feb. 16, 2018 | Jun. 30, 2017 | |
| Document And Entity Information [Abstract] | |||
| Entity Registrant Name | LA JOLLA PHARMACEUTICAL CO | ||
| Entity Central Index Key | 0000920465 | ||
| Document Type | 10-K | ||
| Document Period End Date | Dec. 31, 2017 | ||
| Amendment Flag | false | ||
| Document Fiscal Year Focus | 2017 | ||
| Document Fiscal Period Focus | FY | ||
| Current Fiscal Year End Date | --12-31 | ||
| Entity Well-known Seasoned Issuer | No | ||
| Entity Voluntary Filers | No | ||
| Entity Current Reporting Status | Yes | ||
| Entity Filer Category | Accelerated Filer | ||
| Entity Public Float | $ 512,864,000 | ||
| Entity Common Stock, Shares Outstanding | 22,168,242 |
View differences made from one year to another to evaluate La Jolla Pharmaceutical Co's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by La Jolla Pharmaceutical Co.
Assess how La Jolla Pharmaceutical Co's management team is paid from their Annual Proxy
La Jolla Pharmaceutical Co's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
Tools
Rating
Learn More
Filter by Sentiment:
Filter by Category:
Filter by Subcategory:
-
Other - Other Highlight
The increase in cash provided by financing activities was due to $117.5 million of proceeds from the March 2017 common stock offering and an increase of $2.7 million of proceeds from the exercise of stock options for common stock.
-
Financial - Expense Highlight
In addition, there were increased expenses for professional and outside service costs.
-
Financial - Shares Highlight
Changes in assumptions used under the Black-Scholes option pricing model could materially affect our net loss and net loss per share.
-
Financial - Expense Highlight
The increase was primarily due to increased personnel and related costs and share-based compensation expense as a result of increased headcount associated with the development of GIAPREZA and LJPC-401.
-
Other - Other Highlight
The increase in cash used for investing activities was a result of purchases of property and equipment.
-
Other - Other
The financial terms of these...Read more
-
Other - Other
As a result, the consideration...Read more
-
Financial - Expense
We anticipate research and development...Read more
-
Financial - Expense
We amortize prepayments to expense...Read more
-
Financial - Cash Flow
We have a history of...Read more
-
Financial - Expense
The following summarizes our research...Read more
-
Financial - Expense
The following summarizes our research...Read more
-
Financial - Expense
We anticipate general and administrative...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Consolidated Statements Of Shareholders' Equity
Balance Sheet Account Details
Balance Sheet Account Details (accrued Expenses) (details)
Balance Sheet Account Details (property And Equipment) (details)
Balance Sheet Account Details (tables)
Business
Business (details)
Commitments And Contingencies
Commitments And Contingencies (annual Future Minimum Licensing Payments) (details)
Commitments And Contingencies (annual Future Minimum Payments For Manufacturing And Supply Agreements) (details)
Commitments And Contingencies (annual Future Minimum Payments Under Operating Leases) (details)
Commitments And Contingencies (narrative) (details)
Commitments And Contingencies (tables)
Contract Revenue - Related Party (narrative) (details)
Contract Revenue - Related Party (notes)
Defined Contribution Plan
Defined Contribution Plan (narrative) (details)
Income Taxes
Income Taxes (narrative) (details)
Income Taxes (provision For Income Taxes) (details)
Income Taxes (significant Components Of Deferred Tax Assets) (details)
Income Taxes (tables)
Licensed Technology
Licensed Technology (narrative) (details)
Quarterly Financial Information (unaudited)
Quarterly Financial Information (unaudited) (details)
Quarterly Financial Information (unaudited) (tables)
Shareholders??? Equity
Shareholders??? Equity (narrative) (details)
Shareholders??? Equity (share-based Compensation Expense) (details)
Shareholders??? Equity (stock Option And Restricted Stock Award Activity) (details)
Shareholders??? Equity (stock Options, Valuation Assumptions) (details)
Shareholders??? Equity (summary Of Restricted Stock Awards) (details)
Shareholders??? Equity (tables)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (narrative) (details)
Summary Of Significant Accounting Policies (policies)
Material Contracts, Statements, Certifications & more
La Jolla Pharmaceutical Co provided additional information to their SEC Filing as exhibits
Ticker: LJPC
CIK: 920465
Form Type: 10-K Annual Report
Accession Number: 0000920465-18-000007
Submitted to the SEC: Thu Feb 22 2018 4:52:46 PM EST
Accepted by the SEC: Thu Feb 22 2018
Period: Sunday, December 31, 2017
Industry: Biological Products No Disgnostic Substances
External Resources:
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/ljpc/0000920465-18-000007.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
SEC Filing Financial Summary
Excel Download
Loading SEC Filing Financial Summary...